<DOC>
	<DOC>NCT00536692</DOC>
	<brief_summary>This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.</brief_summary>
	<brief_title>Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Mecamylamine</mesh_term>
	<criteria>macular edema due to diabetic retinopathy vision loss from other ocular disease intraocular surgery within 3 months intraocular antiVEGF or steroids within 3 months HbA1c &gt;12</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>macular edema</keyword>
	<keyword>DME</keyword>
	<keyword>diabetic</keyword>
	<keyword>mecamylamine</keyword>
	<keyword>Comentis</keyword>
</DOC>